Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
4/27/2026, 12:00:00 AM
On April 27, 2026, AbbVie submitted an application to the FDA for a subcutaneous (under-the-skin) induction dosing option for Skyrizi to treat Crohn's disease, offering a more convenient administration method.
Korean Translation
2026년 4월 27일, AbbVie는 크론병 치료를 위한 스카이리치(Skyrizi)의 피하 유도 투여 옵션에 대해 FDA에 허가 신청서를 제출하여 더 편리한 투여 방법을 제공하게 됨.
Related Recent Events
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 fiscal 2027 earnings release is scheduled for May 20, 2026. Low importance assigned as the announcement of an earnings date typically results in ~1% price impact, scheduled.
5/20/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
First quarter 2026 financial results and conference call on May 11, 2026, with high importance estimated due to potential market impact of earnings guidance, scheduled.
5/11/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Earnings Release
First quarter 2026 financial results on May 7, 2026, to be released after market close; significant price impact expected based on recent growth trends scheduled.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is expected to announce its Q1 2026 financial results scheduled. Scheduled earnings releases are key volatility events with an estimated 5% impact.
5/7/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
First quarter 2026 financial results and business update scheduled for May 5, 2026; high impact from potential 10% price volatility expected.
5/5/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
BioNTech will report first-quarter 2026 financial results and provide a corporate update on 2026-05-05; given the sharp March 2026 volatility after guidance and leadership news, this update is likely to be closely watched and could move shares materially, expected.
5/5/2026, 12:00:00 AM